Respiratory Test

Lumos Diagnostic, partnered with Atomo to develop a novel, rapid, point-of-care test that differentiates between viral versus bacterial acute respiratory infection in 10 minutes.

FebriDx Antimicrobial Resistance (AMR) Screening Test

FebriDx Antimicrobial Resistance (AMR) Screening Test
Test platform designed & manufactured by Atomo; Branded & Distributed by Lumos
Sold in Europe and under review with the US FDA
authorized to identify and differentiate viral from bacterial acute respiratory infection. With 99% accuracy, this test has reduced antibiotic prescriptions by 80%, leading to better efficiencies and lower costs.

Finished rapid test products are commercialized under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU/ UK, Australian TGA, and the World Health Organization with FDA approvals pending.

Develop Future Tests With Us

Atomo’s unique technology presents an opportunity to improve existing products on the market with superior usability. Our integrated platforms can help users easily perform the tests on their own and improve performance, speed and reliability in a professional clinical setting.

We welcome dialogue with forward-thinking diagnostic partners who would like to explore co-developing tests for infectious diseases, allergy sensitivities, women’s health, men’s health, sexual health, heart health and other applications.

Re-imagining diagnostics.